Physician profile
Frederick E Kahn
NPI 1316160039
$2,421.60
in general payments reported to CMS, 2019-2025
14 companies · $519 in 2025
The $519 reported for 2025 was more than what 79% of Psychosomatic Medicine providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,602 · 2020: $37.68 · 2024: $263 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $781.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Orexo US, INC. | $1,293.73 | 2019 | |
| Braeburn INC. | $472.58 | 2024-2025 | Brixadi |
| Kerecis Limited | $218.40 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Otsuka America Pharmaceutical, INC. | $166.31 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $109.36 | 2019 | |
| Vanda Pharmaceuticals INC. | $34.88 | 2025 | Hetlioz, Fanapt |
| Indivior INC. | $27.48 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.63 | 2025 | Austedo Xr |
| Lundbeck LLC | $15.00 | 2019 | |
| Allergan, INC. | $14.39 | 2019 | |
| Vertical Pharmaceuticals, LLC | $13.70 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.50 | 2019 | |
| Avanir Pharmaceuticals, INC. | $12.52 | 2020 | |
| Jazz Pharmaceuticals INC. | $12.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Kahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.